Showing 1 - 20 results of 1,142 for search '(( third ((((marked decrease) OR (a decrease))) OR (nn decrease)) ) OR ( non small decrease ))', query time: 0.42s Refine Results
  1. 1

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  2. 2
  3. 3

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  4. 4
  5. 5
  6. 6

    Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

    Published 2025
    “…Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. …”
  7. 7

    Participants enrollment. by Chikondi Maluwa (20660522)

    Published 2025
    “…<div><p>Hypertension is a widespread and life-threatening condition affecting one-third of adults globally. …”
  8. 8

    KAP assessment scores (n = 422). by Chikondi Maluwa (20660522)

    Published 2025
    “…<div><p>Hypertension is a widespread and life-threatening condition affecting one-third of adults globally. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Supplementary file 1_Potential interactions between traditional Chinese medicine and osimertinib: a Case Report.docx by Min Zhang (111999)

    Published 2025
    “…<p>Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. …”
  14. 14
  15. 15
  16. 16

    Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe by Alastair Greystoke (9562178)

    Published 2024
    “…<p>This study estimated avoided recurrences and treatment costs in patients with stage II-IIIA non-small cell lung cancer treated with adjuvant atezolizumab in five European countries over 10 years (2024–2034).…”
  17. 17
  18. 18
  19. 19

    Data and code from: Continental declines in North American small mammal populations by Alec Medd (20968740)

    Published 2025
    “…Contrary to our initial speculation, we found strong support for an overall decline in North American small mammal abundance, with an estimated annual decrease of 3.6%. …”
  20. 20